Zachary Cooper

20PUBLICATIONS
263CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene and molecular therapyBiomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 03, 2025
IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors.

John Powderly, Martina Imbimbo, Antoine Italiano

|Mar 29, 2025
Quantifying CD73 expression after chemotherapy or chemoradiotherapy in esophageal squamous cell carcinoma.

Zachary A Cooper, Ying Wang, Philip L Martin

|Aug 06, 2024
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Andrew L Coveler, Matthew J Reilley, Mark Zalupski

|Jul 24, 2024
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.

Neil H Segal, Jeanne Tie, Scott Kopetz

|May 31, 2023
Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors.

Luana Guimaraes Sousa, Daniel J McGrail, Felippe Lazar Neto

|Apr 04, 2023
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.

Johanna Bendell, Patricia LoRusso, Michael Overman

Pageof 4

Frequent Collaborators

8 joint publications

Jennifer A Wargo

7 joint publications

Alexandre Reuben

6 joint publications

P Andrew Futreal

6 joint publications

Alexander J Lazar